Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma
Pfizer Inc and Debiopharm Group™ have announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for its worldwide commercialization.
For the full story, Click Here
- Bacteria in baby’s gut can help prevent eczema
- Sugary Band-Aid May Help Heal Post-Operative Tissue
- Dermatologists say people not using enough sunscreen
- Medline Introduces Remedy(R) With PhytoplexTM That Replenishes And Protects Sensitive Skin
